Brittany Embry, ATR-P | |
1002 S Virginia St Ste 401, Hopkinsville, KY 42240-3507 | |
(270) 881-2142 | |
Not Available |
Full Name | Brittany Embry |
---|---|
Gender | Female |
Speciality | Art Therapist |
Location | 1002 S Virginia St Ste 401, Hopkinsville, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093497513 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101Y00000X | Counselor | (* (Not Available)) | Secondary |
221700000X | Art Therapist | 23-230 (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Brittany Embry, ATR-P 3739 Tradewinds Ter, Clarksville, TN 37040-6328 Ph: (812) 604-2885 | Brittany Embry, ATR-P 1002 S Virginia St Ste 401, Hopkinsville, KY 42240-3507 Ph: (270) 881-2142 |
News Archive
University of Manchester scientists have uncovered the 3D structure of Mps1 - a protein that regulates the number of chromosomes during cell division and thus has an essential role in the prevention of cancer - which will lead to the design of safer and more effective therapies.
"Signaling the latest step forward in rapidly strengthening U.S.-Somalia relations, the administrator of the U.S. Agency for International Development spent five hours in Mogadishu on Thursday, the highest ranking U.S. administration official to visit Somalia's capital in years," the Associated Press reports.
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, provides an update on its business performance for 2014. MGB Biopharma is developing a pipeline of novel antimicrobials that puts it at the forefront of addressing the major global problem of antimicrobial resistance.
Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.
› Verified 6 days ago